Farxiga Approval Expands Use to More Patients With Heart Failure
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration.
The Trifecta and Trifecta GT valves are heart valve replacement devices designed to treat diseased, damaged, or malfunctioning native or prosthetic aortic heart valves.
The FDA is requiring the Company to conduct an additional clinical trial evaluating omecamtiv mecarbil for HFrEF.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.